In:
Annals of the Rheumatic Diseases, BMJ, Vol. 77, No. 12 ( 2018-12), p. 1710-1719
Abstract:
To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA). Methods Patients (2–19 years) entered two phase III studies and continued in the long-term extension (LTE) study. Efficacy assessments were performed every 3 months, including adapted JIA American College of Rheumatology (aJIA-ACR) criteria, Juvenile Arthritis Disease Activity Score (JADAS) and ACR clinical remission on medication criteria (CR ACR ). Efficacy analyses are reported as per the intent-to-treat population. Results 144 of the 177 patients (81%) enrolled in the core study entered the LTE. Overall, 75 patients (42%) completed and 102 (58%) discontinued mainly for inefficacy (63/102, 62%), with higher discontinuation rates noted in the late responders group (n=25/31, 81%) versus early responders (n=11/38, 29%). At 2 years, aJIA-ACR 50/70/90 response rates were 62%, 61% and 54%, respectively. CR ACR was achieved by 20% of patients at month 6; 32% at 2 years. A JADAS low disease activity score was achieved by 49% of patients at 2 years. Efficacy results were maintained up to 5 years. Of the 128/177 (72.3%) patients on glucocorticoids, 20 (15.6%) discontinued and 28 (22%) tapered to 0.150 mg/kg/day. Seven patients discontinued canakinumab due to CR. There were 13 macrophage activation syndrome (three previously reported) and no additional deaths (three previously reported). No new safety findings were observed. Conclusion Response to canakinumab treatment was sustained and associated with substantial glucocorticoid dose reduction or discontinuation and a relatively low retention-on-treatment rate. No new safety findings were observed on long-term use of canakinumab. Trial registration numbers NCT00886769 , NCT00889863 , NCT00426218 and NCT00891046 .
Type of Medium:
Online Resource
ISSN:
0003-4967
,
1468-2060
DOI:
10.1136/annrheumdis-2018-213150
DOI:
10.1136/annrheumdis-2018-213150.supp7
DOI:
10.1136/annrheumdis-2018-213150.supp3
DOI:
10.1136/annrheumdis-2018-213150.supp4
DOI:
10.1136/annrheumdis-2018-213150.supp1
DOI:
10.1136/annrheumdis-2018-213150.supp2
DOI:
10.1136/annrheumdis-2018-213150.supp5
DOI:
10.1136/annrheumdis-2018-213150.supp6
Language:
English
Publisher:
BMJ
Publication Date:
2018
detail.hit.zdb_id:
1481557-6
detail.hit.zdb_id:
7090-7
Permalink